- Home
- BB vs BEAM Comparison
BB vs BEAM Comparison
Compare BB & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BB | BEAM |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BB | BEAM |
|---|---|---|
| Price | $3.77 | $27.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $4.98 | ★ $48.09 |
| AVG Volume (30 Days) | ★ 9.1M | 1.6M |
| Earning Date | 12-18-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $534,799,999.00 | $55,701,000.00 |
| Revenue This Year | $3.25 | N/A |
| Revenue Next Year | $7.91 | $26.52 |
| P/E Ratio | $104.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.80 | $13.53 |
| 52 Week High | $6.24 | $35.25 |
Technical Indicators
Market Signals| Indicator | BB | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 35.93 | 57.03 |
| Support Level | $3.71 | $26.71 |
| Resistance Level | $3.99 | $28.70 |
| Average True Range (ATR) | 0.17 | 1.19 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 7.43 | 63.72 |
Price Performance
Historical ComparisonAbout BB BlackBerry Limited
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.